In this era of personalized medicine, in which every patient is supposed to be treated using a therapeutic plan that is tailored to provide the right care at the right time and in the right place, it is surprising how little attention has been paid to personalizing follow-up for patients after curative treatment of cancer. This is certainly true in localized cutaneous melanoma, for which there is little if any consensus with regard to standard follow-up strategies and virtually no guidance with regard to how to individualize follow-up on the basis of a patient’s estimated risk of requiring additional interventions. Should we (and our patients) care about this deficiency?
Read more: Individualizing Follow-Up for Patients With Early-Stage Melanoma
